Local interleukin-2 therapy in bovine ocular squamous cell carcinoma - A pilot study

V. P.M.G. Rutten; W. R. Klein; W. H. De Jong; W. Misdorp; W. Den Otter; P. A. Steerenberg; W. H. De Jong; E. J. Ruitenberg

doi:10.1007/BF01669425

Local interleukin-2 therapy in bovine ocular squamous cell carcinoma - A pilot study

V. P.M.G. Rutten^*, W. R. Klein, W. H. De Jong, W. Misdorp, W. Den Otter, P. A. Steerenberg, W. H. De Jong, E. J. Ruitenberg

^*Corresponding author for this work

Immunology

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Five cows bearing bovine ocular squamous cell carcinoma (BOSCC) were treated with low doses of recombinant human interleukin-2 (rhIL-2). A dose of 2500 U rhIL-2 was injected intralesionally and another 2500 U were injected into the subparotid regional lymph node once a day during a period of 5 consecutive days. This cycle of 5 days was repeated after an interval of 2 days. Total regression of the tumor was observed in three out of five animals. One cow showed tumor regression (> 80%) accompanied by metastases to the regional lymph node that were observed from the fifth week after the beginning of the treatment. Growth of the tumor of the fifth animal was retarded after treatment. In vitro proliferation of peripheral blood lymphocytes was investigated in two animals and tumor-infiltrating lymphocytes in one animal during incubation in various rhIL-2 concentrations. Cytotoxic activity of both cell populations against P815, Yac-1 and BOSCC-derived cell lines increased during incubation with rhIL-2. Cultured BOSCC-infiltrating lymphocytes showed predominant killing of the BOSCC-derived autologous cell line after 4 weeks of culture. Preliminary phenotype analysis did not give conclusive results with respect to the types of cells responsible for killing.

Original language	English
Pages (from-to)	165-169
Number of pages	5
Journal	Cancer Immunology Immunotherapy
Volume	30
Issue number	3
DOIs	https://doi.org/10.1007/BF01669425
Publication status	Published - May 1989

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF01669425

Cite this

@article{05b47de098964fa9aedc05f63309c9cb,

title = "Local interleukin-2 therapy in bovine ocular squamous cell carcinoma - A pilot study",

abstract = "Five cows bearing bovine ocular squamous cell carcinoma (BOSCC) were treated with low doses of recombinant human interleukin-2 (rhIL-2). A dose of 2500 U rhIL-2 was injected intralesionally and another 2500 U were injected into the subparotid regional lymph node once a day during a period of 5 consecutive days. This cycle of 5 days was repeated after an interval of 2 days. Total regression of the tumor was observed in three out of five animals. One cow showed tumor regression (> 80%) accompanied by metastases to the regional lymph node that were observed from the fifth week after the beginning of the treatment. Growth of the tumor of the fifth animal was retarded after treatment. In vitro proliferation of peripheral blood lymphocytes was investigated in two animals and tumor-infiltrating lymphocytes in one animal during incubation in various rhIL-2 concentrations. Cytotoxic activity of both cell populations against P815, Yac-1 and BOSCC-derived cell lines increased during incubation with rhIL-2. Cultured BOSCC-infiltrating lymphocytes showed predominant killing of the BOSCC-derived autologous cell line after 4 weeks of culture. Preliminary phenotype analysis did not give conclusive results with respect to the types of cells responsible for killing.",

author = "Rutten, {V. P.M.G.} and Klein, {W. R.} and {De Jong}, {W. H.} and W. Misdorp and {Den Otter}, W. and Steerenberg, {P. A.} and {De Jong}, {W. H.} and Ruitenberg, {E. J.}",

year = "1989",

month = may,

doi = "10.1007/BF01669425",

language = "English",

volume = "30",

pages = "165--169",

journal = "Cancer Immunology Immunotherapy",

issn = "0340-7004",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "3",

}

TY - JOUR

T1 - Local interleukin-2 therapy in bovine ocular squamous cell carcinoma - A pilot study

AU - Rutten, V. P.M.G.

AU - Klein, W. R.

AU - De Jong, W. H.

AU - Misdorp, W.

AU - Den Otter, W.

AU - Steerenberg, P. A.

AU - De Jong, W. H.

AU - Ruitenberg, E. J.

PY - 1989/5

Y1 - 1989/5

N2 - Five cows bearing bovine ocular squamous cell carcinoma (BOSCC) were treated with low doses of recombinant human interleukin-2 (rhIL-2). A dose of 2500 U rhIL-2 was injected intralesionally and another 2500 U were injected into the subparotid regional lymph node once a day during a period of 5 consecutive days. This cycle of 5 days was repeated after an interval of 2 days. Total regression of the tumor was observed in three out of five animals. One cow showed tumor regression (> 80%) accompanied by metastases to the regional lymph node that were observed from the fifth week after the beginning of the treatment. Growth of the tumor of the fifth animal was retarded after treatment. In vitro proliferation of peripheral blood lymphocytes was investigated in two animals and tumor-infiltrating lymphocytes in one animal during incubation in various rhIL-2 concentrations. Cytotoxic activity of both cell populations against P815, Yac-1 and BOSCC-derived cell lines increased during incubation with rhIL-2. Cultured BOSCC-infiltrating lymphocytes showed predominant killing of the BOSCC-derived autologous cell line after 4 weeks of culture. Preliminary phenotype analysis did not give conclusive results with respect to the types of cells responsible for killing.

AB - Five cows bearing bovine ocular squamous cell carcinoma (BOSCC) were treated with low doses of recombinant human interleukin-2 (rhIL-2). A dose of 2500 U rhIL-2 was injected intralesionally and another 2500 U were injected into the subparotid regional lymph node once a day during a period of 5 consecutive days. This cycle of 5 days was repeated after an interval of 2 days. Total regression of the tumor was observed in three out of five animals. One cow showed tumor regression (> 80%) accompanied by metastases to the regional lymph node that were observed from the fifth week after the beginning of the treatment. Growth of the tumor of the fifth animal was retarded after treatment. In vitro proliferation of peripheral blood lymphocytes was investigated in two animals and tumor-infiltrating lymphocytes in one animal during incubation in various rhIL-2 concentrations. Cytotoxic activity of both cell populations against P815, Yac-1 and BOSCC-derived cell lines increased during incubation with rhIL-2. Cultured BOSCC-infiltrating lymphocytes showed predominant killing of the BOSCC-derived autologous cell line after 4 weeks of culture. Preliminary phenotype analysis did not give conclusive results with respect to the types of cells responsible for killing.

UR - http://www.scopus.com/inward/record.url?scp=0024376550&partnerID=8YFLogxK

U2 - 10.1007/BF01669425

DO - 10.1007/BF01669425

M3 - Article

C2 - 2598185

AN - SCOPUS:0024376550

SN - 0340-7004

VL - 30

SP - 165

EP - 169

JO - Cancer Immunology Immunotherapy

JF - Cancer Immunology Immunotherapy

IS - 3

ER -

Local interleukin-2 therapy in bovine ocular squamous cell carcinoma - A pilot study

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this